Laboratório Interdisciplinar de Neurociências Clínicas (LiNC), Departamento de Psiquiatria, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil.
Divisão de Psiquiatria, Departamento de Neurociências e Ciências do Comportamento, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (FMRP-USP), Ribeirão Preto, São Paulo, SP, Brazil.
Braz J Psychiatry. 2021 Sep-Oct;43(5):467-476. doi: 10.1590/1516-4446-2020-1416.
To assess the efficacy of cannabidiol (CBD) in the management of crack-cocaine craving and the treatment of frequent withdrawal symptoms.
Thirty-one men with a diagnosis of crack-cocaine dependence were enrolled in a randomized, double-blind, placebo-controlled trial. We applied neuropsychological tests and assessed craving intensity, anxiety and depression symptoms, and substance use patterns at baseline and at the end of the trial. The participants were treated with CBD 300 mg/day or placebo for 10 days. During this period, we used a technique to induce craving and assessed the intensity of symptoms before and after the induction procedure.
Craving levels reduced significantly over the 10 days of the trial, although no differences were found between the CBD and placebo groups. Craving induction was successful in both groups, with no significant differences between them. Indicators of anxiety, depression, and sleep alterations before and after treatment also did not differ across groups.
Under the conditions of this trial, CBD was unable to interfere with symptoms of crack-cocaine withdrawal. Further studies with larger outpatient samples involving different doses and treatment periods would be desirable and timely to elucidate the potential of CBD to induce reductions in crack-cocaine self-administration.
评估大麻二酚（CBD）在管理可卡因渴望和治疗频繁戒断症状方面的疗效。
31 名被诊断为可卡因依赖的男性参加了一项随机、双盲、安慰剂对照试验。我们应用神经心理学测试，在基线和试验结束时评估渴望强度、焦虑和抑郁症状以及物质使用模式。参与者接受 CBD 300mg/天或安慰剂治疗 10 天。在此期间，我们使用一种诱发渴望的技术，并在诱导程序前后评估症状的强度。
尽管 CBD 组和安慰剂组之间没有差异，但在 10 天的试验期间，渴望水平显著降低。两组的渴望诱导均成功，两组之间无显著差异。治疗前后焦虑、抑郁和睡眠改变的指标在组间也没有差异。
在本试验条件下，CBD 不能干扰可卡因戒断症状。进一步的研究需要更大的门诊样本，涉及不同的剂量和治疗期，以阐明 CBD 诱导减少可卡因自我给药的潜力是及时和可取的。
